Related Experiment Video

Updated: Aug 23, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and

Hande Beklen1, Sema Arslan2, Gizem Gulfidan1

  • 1Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.

Frontiers in Bioinformatics
|October 28, 2022
PubMed

Insights

This study identifies novel biomarkers and drug candidates for colorectal cancer (CRC) treatment using a novel interactome-based drug repositioning strategy. Several drugs showed significant in vitro efficacy, offering new therapeutic avenues for CRC.

Area of Science:

  • Oncology
  • Bioinformatics
  • Pharmacology

Background:

  • Colorectal cancer (CRC) necessitates innovative treatment strategies.
  • Identifying reliable biomarkers and effective drug candidates is crucial for improving CRC patient outcomes.

Purpose of the Study:

  • To propose novel biomarkers and drug candidates for colorectal cancer (CRC) treatment.
  • To utilize differential interactome-based drug repositioning for identifying therapeutic targets and drugs.

Main Methods:

  • Identification of differentially interacting proteins and modules with prognostic value using survival analyses.
  • Drug repositioning targeting significant proteins, followed by in silico molecular docking.
  • In vitro validation of candidate drugs using colorectal cancer (CRC) cell lines.

Main Results:

  • Six key modules (mAPEX1, mCCT7, mHSD17B10, mMYC, mPSMB5, mRAN) were identified for their prognostic significance.
  • Eight potential drugs were repositioned, including abacavir, ribociclib, exemestane, voriconazole, nortriptyline hydrochloride, theophylline, bromocriptine mesylate, and tolcapone.
  • Significant in vitro inhibition was observed for abacavir, nortriptyline hydrochloride, exemestane, tolcapone, and theophylline in CRC cell lines.

Conclusions:

  • The study presents a novel approach for colorectal cancer (CRC) treatment strategy development.
  • Identified biomarkers and repositioned drugs offer potential complementary therapeutic options for CRC.
Keywords:
colorectal cancerdifferential interactomedrug repositioningprognostic markerssystems biomarkers

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
298
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
374
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
246
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.1K